Skip to main content

Table 4 Study withdrawals during the 21-day stabilization period (ITT Population)

From: Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation

Patients withdrawing from study during 21-day stabilization period

FP/SAL 250/50 μg (N = 314)

SAL 50 μg (N = 325)

NominalPValue*

Any reason

26 (8%)

39 (15%)

.105

For lack of efficacy or adverse event

15 (5%)

24 (7%)

.158

For lack of efficacy

5 (2%)

13 (4%)

.062

  1. All data are n (%).
  2. *Nominal P-values are from Cochran-Mantel-Haenzel tests controlling for randomization stratum.
  3. FP = fluticasone propionate; ITT = intent-to-treat; SAL = salmeterol.